Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nepafenac 0.3% after cataract surgery
NL-OMON34348Phase 3Withdrawn
- Sponsor
- Alcon Inc.
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nepafenac in Postoperative ocular inflammation and post-operative ocular pain (4 arms), sponsored by Alcon Inc. Primary endpoint: Clinical cure at day 14. Planned start Aug 2010; status: withdrawn.
02
Drugs
nepafenac
03
Conditions
Postoperative ocular inflammationpost-operative ocular pain
Beyond the preview
Go deeper on NL-OMON34348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34348.